CorMedix Announces Strategic Minority Investment in Talphera
1. CorMedix invested $5 million in Talphera, acquiring 9 million shares. 2. Talphera is developing Niyad™, an anticoagulant with Breakthrough Device Designation. 3. Niyad is aimed at patients undergoing continuous renal replacement therapy. 4. CorMedix gains right of first negotiation for Talphera acquisition. 5. Niyad could set a new standard of care in acute hospital settings.